Intuitive Surgical Inc (ISRG)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $153.77B
Last updated: Nov 17, 2026 at 11:06 AM ET
Intuitive Surgical Inc (ISRG) Financials: Revenue, Profit and Cash Flow
Intuitive Surgical reported revenue of $10.06B for the fiscal year ended Dec 31, 2025, up 20.5% from the year before. That year, net income was $2.88B with a net margin of 28.6%, operating cash flow was $3.03B and free cash flow was $2.49B. The quarter ended Sep 30, 2026 had revenue of $3.05B and net income of $524.40M.
Revenue and Margins
The operating margin was 29.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $2.71B, a compound annual rate of 15.7%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $10.06B | +20.5% | 66.0% | 29.3% | 28.6% |
| Dec 2024 | $8.35B | +17.2% | 67.5% | 28.1% | 28.0% |
| Dec 2023 | $7.12B | +14.5% | 66.4% | 24.8% | 25.5% |
| Dec 2022 | $6.22B | +9.0% | 67.4% | 25.3% | 21.6% |
| Dec 2021 | $5.71B | +31.0% | 69.3% | 31.9% | 30.3% |
| Dec 2020 | $4.36B | -2.7% | 65.6% | 24.1% | 24.5% |
| Dec 2019 | $4.48B | +20.3% | 69.4% | 30.7% | 30.9% |
| Dec 2018 | $3.72B | +18.7% | 69.9% | 32.2% | 30.2% |
| Dec 2017 | $3.14B | +16.0% | 70.2% | 33.9% | 21.4% |
| Dec 2016 | $2.71B | N/A | 69.9% | 35.1% | 27.3% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 23.1% from the year before. In the quarter ended Sep 2026, net income fell 26.1% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.06B | $8.35B | $7.12B | $6.22B | $5.71B | $4.36B | $4.48B | $3.72B | $3.14B | $2.71B |
| Cost of revenue | $3.42B | $2.72B | $2.39B | $2.03B | $1.75B | $1.50B | $1.37B | $1.12B | $936.20M | $813.60M |
| Gross profit | $6.64B | $5.63B | $4.73B | $4.20B | $3.96B | $2.86B | $3.11B | $2.60B | $2.20B | $1.89B |
| Research and development | $1.31B | $1.15B | $998.80M | $879.00M | $671.00M | $595.10M | $557.30M | $418.10M | $328.60M | $239.60M |
| Operating income | $2.95B | $2.35B | $1.77B | $1.58B | $1.82B | $1.05B | $1.37B | $1.20B | $1.06B | $949.70M |
| Net income | $2.88B | $2.34B | $1.82B | $1.34B | $1.73B | $1.07B | $1.38B | $1.13B | $670.90M | $738.30M |
| EBITDA | $3.93B | $3.13B | $2.42B | $2.05B | $2.23B | $1.45B | $1.71B | $1.41B | $1.24B | $1.12B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.05B | $2.89B | $2.77B | $2.87B | $2.51B | $2.44B | $2.25B | $2.41B | $2.04B | $2.01B | $1.89B | $1.93B |
| Gross profit | $2.08B | $1.96B | $1.83B | $1.90B | $1.66B | $1.62B | $1.46B | $1.64B | $1.37B | $1.37B | $1.25B | $1.28B |
| Operating income | $592.60M | $971.90M | $855.30M | $864.30M | $759.70M | $743.40M | $578.10M | $734.90M | $577.30M | $567.30M | $469.40M | $450.20M |
| Net income | $524.40M | $823.20M | $826.00M | $799.50M | $709.20M | $664.20M | $703.70M | $688.00M | $570.60M | $531.50M | $547.40M | $610.70M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $549.80M by $2.82B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $20.46B | $18.74B | $15.44B | $12.97B | $13.55B | $11.17B | $9.73B | $7.85B | $5.78B | $6.49B |
| Current assets | $9.78B | $7.11B | $7.89B | $6.25B | $5.84B | $6.63B | $4.66B | $4.33B | $2.81B | $3.25B |
| Cash and equivalents | $3.37B | $2.03B | $2.75B | $1.58B | $1.29B | $1.62B | $1.17B | $857.90M | $648.20M | $1.04B |
| Total liabilities | $2.52B | $2.21B | $2.04B | $1.86B | $1.60B | $1.41B | $1.45B | $1.16B | $996.40M | $709.10M |
| Short-term debt | $39.00M | $33.50M | $25.30M | $24.20M | $20.40M | $21.90M | $568.90M | $39.10M | $371.90M | $143.70M |
| Long-term debt | $510.80M | $468.30M | $385.50M | $439.30M | $453.70M | $444.60M | $418.30M | $338.60M | $333.60M | $0 |
| Shareholder equity | $17.82B | $16.43B | $13.31B | $11.04B | $11.90B | $9.73B | $8.26B | $6.68B | $4.78B | $5.78B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $19.35B | $20.88B | $20.11B | $20.63B | $19.35B | $20.16B | $19.22B | $18.84B | $17.74B | $16.65B | $15.83B | $15.44B |
| Total liabilities | $3.23B | $2.58B | $2.51B | $2.69B | $2.31B | $2.21B | $2.01B | $2.31B | $2.07B | $1.85B | $1.78B | $2.04B |
| Cash and equivalents | $2.98B | $2.76B | $2.01B | $3.37B | $2.81B | $3.40B | $2.57B | $2.03B | $2.41B | $3.04B | $2.84B | $2.75B |
| Shareholder equity | $15.99B | $18.17B | $17.47B | $17.82B | $16.93B | $17.85B | $17.11B | $16.43B | $15.58B | $14.71B | $13.96B | $13.31B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 82.2% of operating cash flow. Share repurchases came to 92.4% of it, with no dividends.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.03B | $2.42B | $1.81B | $1.49B | $2.09B | $1.48B | $1.60B | $1.17B | $1.14B | $1.09B |
| Capital expenditures | $539.80M | $1.11B | $1.06B | $532.40M | $339.50M | $341.50M | $425.60M | $187.40M | $190.70M | $53.90M |
| Free cash flow | $2.49B | $1.30B | $749.60M | $958.40M | $1.75B | $1.14B | $1.17B | $982.20M | $953.20M | $1.03B |
| Dividends paid | $0 | $8.00M | $0 | $0 | N/A | N/A | N/A | N/A | $0 | $0 |
| Share repurchases | $2.30B | $0 | $416.30M | $2.61B | $0 | $134.30M | $269.50M | $0 | $2.27B | $42.50M |
| Investing cash flow | $665.80M | -$3.27B | -$360.10M | $1.37B | -$2.46B | -$940.60M | -$1.15B | -$1.05B | $378.70M | -$1.28B |
| Financing cash flow | -$2.36B | $150.90M | -$287.60M | -$2.57B | $43.00M | -$85.70M | -$168.40M | $126.30M | -$1.91B | $514.40M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.22B | $1.06B | $911.90M | $892.50M | $841.00M | $715.40M | $581.60M | $822.60M | $706.50M | $620.50M | $265.40M | $228.30M |
| Capital expenditures | $113.10M | $112.60M | $103.30M | $162.50M | $105.40M | $155.30M | $116.60M | $312.00M | $247.90M | $309.40M | $241.90M | $435.50M |
| Free cash flow | $1.11B | $948.40M | $808.60M | $730.00M | $735.60M | $560.10M | $465.00M | $510.60M | $458.60M | $311.10M | $23.50M | -$207.20M |
Frequently Asked Questions About ISRG
What is Intuitive Surgical's annual revenue?
Intuitive Surgical reported revenue of $10.06B for the fiscal year ended Dec 31, 2025.
How fast is Intuitive Surgical's revenue growing?
Revenue was up 20.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 17.4%.
Is Intuitive Surgical profitable?
Yes. Intuitive Surgical reported net income of $2.88B for the fiscal year ended Dec 31, 2025, with a net margin of 28.6%.
How much free cash flow does ISRG generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $3.03B minus capital expenditures of $539.80M produced free cash flow of $2.49B.
How much debt does Intuitive Surgical have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $510.80M, short-term debt of $39.00M and cash and equivalents of $3.37B.
ISRG pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts